+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Proton therapy for non-small cell lung cancer: Current evidence and future directions



Proton therapy for non-small cell lung cancer: Current evidence and future directions



Thoracic Cancer 3(2): 99-108



Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Radiation dose escalation can improve survival in NSCLC patients but is often limited by adverse effects. One promising radiotherapy modality is proton radiotherapy, which, because of its physical characteristics, delivers minimal exit dose beyond the target volume and thus results in better sparing of normal tissues than does photon radiotherapy. Passive-scattering proton therapy and intensity-modulated proton therapy have shown promise in the treatment of early-stage and locally advanced non-small cell lung cancer. However, more studies are needed to optimize proton therapy, particularly intensity-modulated proton therapy, to address motion and density changes and to guide appropriate patient selection.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060148734

Download citation: RISBibTeXText

PMID: 28920298

DOI: 10.1111/j.1759-7714.2011.00095.x


Related references

Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions. Cancers 7(3): 1178-1190, 2015

EGFR inhibition in non-small cell lung cancer: current evidence and future directions. Biomarker Research 1(1): 2, 2013

Adjuvant therapy in non-small cell lung cancer: current and future directions. Oncologist 15(8): 862-872, 2010

Intratumoral gene therapy for non-small cell lung cancer: current status and future directions. Monaldi Archives for Chest Disease 59(4): 287-295, 2004

PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist 24(Suppl 1): S31-S41, 2019

Current Status and Future Directions of Multimodality Therapy for Non- Small Cell Lung Cancer of the Superior Sulcus. Current Cancer Therapy Reviews 7(1): 2-9, 2011

Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions. Critical Reviews in Oncology/Hematology 82(3): 338-360, 2012

Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy. Oncology 16(6 Suppl 6): 53-62, 2002

Stereotactic body radiation therapy vs. surgery in early-stage non-small cell lung cancer: lessons learned, current recommendations, future directions. Journal of Thoracic Disease 10(3): 1201-1204, 2018

Antivascular agents for non-small-cell lung cancer: current status and future directions. Expert Opinion on Investigational Drugs 18(11): 1667-1686, 2010

The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Seminars in Oncology 21(3 Suppl 6): 49-59, 1994

Future directions in the therapy of small cell lung cancer. Chest Surgery Clinics of North America 7(1): 183-194, 1997

Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(8): 1294-1300, 2000

Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. Journal of Thoracic Oncology 9(11): 1609-1617, 2015

Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions. Briefings in Functional Genomics 2018, 2018